Managers / Q4 2022 · view latest →
Artia Global Partners LP
CIK 0001937964 · 1 SE 3RD AVENUE, STE 2120, MIAMI, FL, 33131 · 3057101384
Summary
Artia Global Partners LP reported $262M in U.S.-listed holdings across 25 positions for Q4 2022.
Its largest position, NVO, represents 19.1% of the portfolio.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 55.0% · $144M
- ADR · 36.0% · $94M
- Other · 9.1% · $24M
Quarter-over-Quarter Changes full breakdown →
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| NVONOVO-NORDISK A S | NEW | +371.1K | 371.1K | +$50M | $50M |
| LLYLILLY ELI & CO | NEW | +104.3K | 104.3K | +$38M | $38M |
| ARGXARGENX SE | NEW | +85.2K | 85.2K | +$32M | $32M |
| MRKMERCK & CO INC | NEW | +264.2K | 264.2K | +$29M | $29M |
| KARUNA THERAPEUTICS INC | NEW | +99.3K | 99.3K | +$20M | $20M |
| ABBVABBVIE INC | NEW | +90.8K | 90.8K | +$15M | $15M |
| MRNAMODERNA INC | NEW | +74.7K | 74.7K | +$13M | $13M |
| OPHTEURIVERIC BIO INC | NEW | +504.6K | 504.6K | +$11M | $11M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2022
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $499M | 50 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $706M | 55 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $631M | 51 | Nov 14, 2025 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2025 | $416M | 37 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $395M | 38 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $280M | 37 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $367M | 45 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $517M | 46 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $498M | 49 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $344M | 31 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $241M | 27 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $290M | 34 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $271M | 36 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $262M | 25 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.